Wave Life Sciences rises after positive data on muscle disorder drug

Drug developer Wave Life Sciences' WVE.O shares rise 16.1% to $10.96 premarket

WVE says its experimental drug, WVE-N531, showed functional benefits and reversal of muscle damage in patients with Duchenne muscular dystrophy (DMD) in a mid-stage study

Most DMD patients lack the protein dystrophin which keeps muscles intact

Co intends to submit a marketing application to the FDA in 2026 for potential accelerated approval

Co says 7 out of 8 patients "achieved greater than 5% average dystrophin between 24 and 48 weeks"

Brokerage Truist Securities says the 48-week data is "impressive" for muscle damage reversal

Up to last close, WVE has risen 63.3% in the past 12 months